Eisai Co.,Ltd. (ESALF.PK)
35.67USD
25 Nov 2009
$0.00 (+0.00%)
$35.67
--
$35.67
$35.67
500
50
$37.78
$28.75
ESALF.PK
About
Overall
| Beta: | 0.79 |
| Market Cap (Mil.): | $940,201.81 |
| Shares Outstanding (Mil.): | 284.91 |
| Annual Dividend: | -- |
| Yield (%): | -- |
Financials
| ESALF.PK | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | -- | 1.96 | 3.76 |
| EPS (TTM): | -- | -- | -- |
| ROI: | -- | 0.92 | 2.30 |
| ROE: | -- | 1.27 | 2.82 |
UPDATE 3-Deals of the day -- mergers and acquisitions
** British stockbroker Execution Holdings said it had agreed to buy small-cap focused investment bank Noble Group, in a deal aimed at creating a new firm capable of competing more effectively with big investment banks. [ID:nLDE5BH09Z]
Eisai says to launch 4 drugs in U.S. in 2010/11
TOKYO, Dec 18 (Reuters) - Eisai Co , Japan's fourth-largest drugmaker, said on Friday it expects to launch four drugs in the United States in the year to March 2011, including cancer drug Eribulin and sepsis medication Eritoran.
Nikkei slips 0.2 pct; banks, resource shares fall
* Bank stocks hurt by Basel Committee proposal - analysts
UPDATE 1-Japan's Eisai to buy US drug firm AkaRx for $255 mln
* Cuts net profit forecast by 36 pct due to acquisition
Japan's Eisai to buy US drug firm AkaRx for $255 mln
TOKYO, Dec 18 (Reuters) - Japanese drugmaker Eisai said on Friday it would acquire AkaRx Inc of the United States for $255 million.
Nikkei down but airlines climb on "open skies" deal
TOKYO, Dec 14 (Reuters) - Japan's Nikkei stock average edged down 0.2 percent on Monday, with tech shares such as Kyocera Corp losing ground even as exporters gained on a weaker yen after upbeat U.S. consumer data buoyed optimism about an economic recovery.
Bayer starts Phase III study for Alzheimer test
FRANKFURT, Nov 30 (Reuters) - Bayer has started enrolling participants for the last stage of testing of its Alzheimer's marker florbetaben, which could offer a way to diagnose early onset of the disease, the drugmaker said on Monday.
FDA warns Shire, Eisai on promotions
WASHINGTON (Reuters) - U.S. regulators have warned Shire PLC and Eisai Co Ltd about drug promotions that minimized the medicines' risks and overstated benefits, letters released on Friday said.
UPDATE 1-US FDA warns Shire, Eisai on promotions
WASHINGTON, Nov 13 (Reuters) - U.S. regulators have warned Shire PLC and Eisai Co Ltd about drug promotions that minimized the medicines' risks and overstated benefits, letters released on Friday said.
UPDATE 3-Takeda holds forecast, drugs outlook still tough
* Tough sales in markets, falling sales in flagship drugs
Earnings vs 
Estimates
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
